Find Paper, Faster
Example:10.1021/acsami.1c06204 or Chem. Rev., 2007, 107, 2411-2502
Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease.
Ophthalmology  (IF12.079),  Pub Date : 2020-04-17, DOI: 10.1016/j.ophtha.2020.04.009
Jennifer Lee,Anjum F Koreishi,Katelyn B Zumpf,Caroline L Minkus,Debra A Goldstein


Evaluate the efficacy of weekly adalimumab (ADA) in patients with non-infectious ocular inflammation who failed standard every other week (EOW) dosing.


Single-center, retrospective, study.


Patients with uncontrolled inflammation on ADA EOW who were escalated to weekly dosing.


Chart review conducted at Northwestern University, January 2012 to April 2019.

Outcome: Number of treatment successes on weekly ADA at 6 and 12 months.


Fourteen of 25 patients (56%) achieved disease control at 6 months; no additional failures occurred at 12 months.


Weekly ADA is a reasonable treatment option in patients with recalcitrant inflammation on standard dosing.